What Makes AnaptysBio (ANAB) an Investment Bet?
Laughing Water Capital’s Q2 2026 investor letter said its Class A portfolio returned about 39.8% net of fees in Q2 and 33.6% YTD. The letter highlighted AnaptysBio (NASDAQ:ANAB) as a newly added position after a taxable spinoff. It cited ANAB’s July 13 close at $69.81 and described a July 14-17 trial involving GSK over Jemperli royalties.
How this was made
The 30-second read
Why it matters
The key tradable element is the upcoming July 14-17 trial date tied to ANAB’s allegation that GSK violated the commercial agreement, which could drive volatility and potential repricing of expected royalty recovery or settlement terms.
Market read
ANAB is presented as a special situation with a near-term legal catalyst, but the article does not provide new primary legal or financial data beyond the trial scheduling and the author’s scenario analysis.
What to watch
Settlement probability, litigation duration, and how royalty economics translate into equity value are not evidenced with new filings or financial disclosures in the text.
Background
Laughing Water Capital’s Q2 2026 investor letter highlights AnaptysBio after a taxable spinoff, describing ANAB as primarily collecting royalties on Jemperli sales via a GSK partnership.
Ticker impact
The article says AnaptysBio is an asset-light royalty company after a spinoff, and it accuses GSK of contract violations with a trial set July 14-17.
Elevated volatility likely into and during the July 14-17 trial window; direction depends on settlement odds versus trial outcome.
The text provides a specific upcoming legal-trial date and describes potential outcomes (settlement or recovery of Jemperli value), but it is an investor-letter/promo framing rather than a primary court filing or new evidentiary disclosure.
Market effects
Highlights how royalty-model biotech structures can create binary outcomes tied to commercial-contract disputes.
No clear regional spillover beyond US-listed biotech trading.
Limited; dispute involves a global pharma partner (GSK) but no broader regulatory or market-wide change is described.
Counterpoint
The article is largely promotional and based on an investor letter; without new court documents or filings, the “nearly $300” and 50-80% upside claims may be speculative and not reliably tradable.
Key entities
- companyAnaptysBio, Inc.
NASDAQ-listed clinical-stage biotech described as an asset-light royalty company post-spinoff, with a scheduled July 14-17 trial over alleged GSK contract violations.
- companyGSK
Partner commercializing Jemperli; accused of violating the commercial agreement per the article, with trial set for July 14-17.
- investment_firmLaughing Water Capital
Investment management firm whose Q2 2026 investor letter is cited as the source of the ANAB thesis.
